https://www.geneostx.com/vgxi-and-geneos-therapeutics-expand-partnership-for-personalized-cancer-immunotherapies/ 2021-09-08T07:15:13+00:00 https://www.geneostx.com/vgxi-enables-rapid-gmp-dna-manufacturing-timeline-for-geneos-therapeutics-personalized-cancer-immunotherapy/ 2021-09-08T07:19:49+00:00 https://www.geneostx.com/texas-based-cmo-vgxi-and-geneos-therapeutics-establish-supply-agreement-for-production-of-gt-epic-based-personalized-cancer-therapeutics/ 2021-09-08T17:46:09+00:00 https://www.geneostx.com/geneos-therapeutics-announces-clinical-updates-on-personalized-cancer-vaccine-program/ 2021-09-08T17:47:18+00:00 https://www.geneostx.com/geneos-therapeutics-secures-12-million-in-series-a1-financing-to-advance-personalized-cancer-immunotherapy-programs/ 2021-09-08T17:48:21+00:00 https://www.geneostx.com/geneos-personalized-neoantigen-targeting-vaccine-gnos-pv02-to-be-utilized-in-innovative-gt-30-hepatocellular-carcinoma-trial/ 2021-09-08T17:49:43+00:00 https://www.geneostx.com/geneos-therapeutics-secures-10-5-million-in-series-a-financing-to-develop-the-next-generation-of-neoantigen-targeting-cancer-immunotherapies/ 2021-09-10T15:29:40+00:00 https://www.geneostx.com/geneos-therapeutics-secures-17-million-in-series-a2-financing-to-advance-personalized-cancer-immunotherapy-platform/ 2022-03-24T14:10:10+00:00 https://www.geneostx.com/geneos-announces-expansion-of-leadership-team/ 2022-10-12T15:41:04+00:00 https://www.geneostx.com/geneos-to-highlight-clinical-and-supportive-pharmacodynamic-data-from-personalized-therapeutic-cancer-vaccine-phase-1b-2a-clinical-trial-at-sitc-conference/ 2022-10-13T13:12:49+00:00 https://www.geneostx.com/geneos-therapeutics-announces-another-complete-response-in-ongoing-clinical-trial-of-personalized-therapeutic-cancer-vaccination-in-second-line-advanced-liver-cancer/ 2022-12-14T13:06:59+00:00 https://www.geneostx.com/geneos-therapeutics-announces-positive-clinical-data-for-personalized-therapeutic-cancer-vaccines-in-ongoing-liver-cancer-trial/ 2022-12-14T13:07:17+00:00 https://www.geneostx.com/geneos-therapeutics-secures-5-million-in-series-a3-financing/ 2023-04-12T12:18:42+00:00 https://www.geneostx.com/geneos-therapeutics-nominated-for-2023-prix-galien-usa-startup-award/ 2023-07-28T12:11:46+00:00 https://www.geneostx.com/geneos-therapeutics-closes-its-series-a3-financing-with-investment-of-5-million/ 2023-09-27T23:39:48+00:00 https://www.geneostx.com/geneos-therapeutics-announces-eight-of-34-patients-to-achieve-complete-response-complete-molecular-response-or-secondary-resectability-in-ongoing-clinical-trial-of-personalized-therapeutic-cancer-v/ 2023-09-27T23:39:54+00:00 https://www.geneostx.com/geneos-therapeutics-to-present-new-clinical-data-on-gnos-pv02-at-the-2024-american-association-for-cancer-research-aacr-annual-meeting/ 2024-03-06T12:00:21+00:00 https://www.geneostx.com/geneos-therapeutics-announces-positive-phase-1-2-data-for-gt-30-trial-of-personalized-therapeutic-cancer-vaccine/ 2024-04-07T20:30:34+00:00 https://www.geneostx.com/patients-with-aggressive-brain-and-advanced-liver-cancers-treated-with-geneos-personalized-immunotherapy-for-cancer-as-monotherapy-reach-five-years-of-durable-recurrence-free-survival/ 2025-09-18T11:10:25+00:00